IP Library Granted Patent US 12,097,306
Granted Patent B2
US 12,097,306 · App. 16/467,524 · Granted Sep 24, 2024

Conformal coating of biological surfaces

Inventors: Venkat R. Garigapati (Southborough, MA); Tetsuya Matsuura (Cambridge, MA)
Assignee: Takeda Pharmaceutical Company Limited
A61L27/52A61L27/16A61L27/18A61L27/26A61L27/3804A61L27/3834A61L27/54A61L2420/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,097,306
App. No.
16/467,524
Granted
Sep 24, 2024
Kind
B2
Abstract

The invention provides, inter alia, ultra-thin conformal coated biological surfaces, such as living cells, cell clusters, tissues, organs, and hybrid synthetic organs, and methods of making the same, e.g., using click reactive water soluble polymers, under conditions that do not damage or significantly modify the biological surfaces. In some embodiments, the coated biological surfaces are suitable for delivery to a subject in need thereof.

Claims (22)

1. A composition comprising a living cell having a hydrogel conformal coating on the cell's surface, wherein the conformal coating is uniform over the entirety of the surface of the cell, wherein the thickness of the conformal coating is less than about 20 μm, wherein the hydrogel conformal coating comprises a covalently cross-linked network of multi arm polymers that cross-link through a triazole linkage; wherein the network of multi arm polymers comprises polyethylene glycol (PEG), a methacryloyloxyethyl phosphoscholine co-polymer, or a combination thereof.

2. The composition of claim 1 , wherein the network of multi arm polymers comprises a 4-arm 5-10 kDa polyethylene glycol (PEG); or a methacryloyloxyethyl phosphoscholine co-polymer that is 100-200 kDa and 60-90% phosphocholine; or a combination thereof.

3. The composition of claim 2 , wherein the living cell is an insulin- producing cell or a pluripotent stem cell.

4. The composition of claim 3 , further comprising a pharmaceutically acceptable diluent or excipient.

5. The composition of claim 1 , wherein the network of multi arm polymers is formed from a first functionalized multi arm polymer having a functional group and a second functionalized multi arm polymer having a functional group, wherein the functional group of the second functionalized multi arm polymer is reactive with the functional group of the first functionalized multi arm polymer under physiological conditions.

6. The composition of claim 5 , wherein the first functionalized multi arm polymer is a 4-arm 5-10kDa PEG.

7. The composition of claim 5 , wherein the first functionalized multi arm polymer is a methacryloyloxyethyl phosphocholine co-polymer that is 100-200 kDa and 60-90% phosphocholine.

8. The composition of claim 7 , wherein the first functionalized multi arm polymer is a methacryloyloxyethyl phosphocholine-allylamine copolymer.

9. The composition of claim 5 , wherein the functional group of the first functionalized multi arm polymer is a click functional group.

10. The composition of claim 5 , wherein the functional group of the first functionalized multi arm polymer is a dibenzocyclooctyne (DBCO) or azide.

11. The composition of claim 5 , wherein the second functionalized multi arm polymer is a 4-arm 5-10 kDa PEG.

12. The composition of claim 5 , wherein the second functionalized multi arm polymer is a methacryloyloxyethyl phosphocholine co-polymer that is 100-200 kDa and 60-90% phosphocholine.

13. The composition of claim 12 , wherein the second functionalized multi arm polymer is a methacryloyloxyethyl phosphocholine-allylamine copolymer.

14. The composition of claim 5 , wherein the functional group of the second functionalized multi arm polymer is a click functional group.

15. The composition of claim 5 , wherein the functional group of the second functionalized multi arm polymer is a dibenzocyclooctyne (DBCO) or azide.

16. The composition of claim 5 , wherein the functional group of the first functionalized multi arm polymer and the functional group of the second functionalized multi arm polymer react to form a triazole.

17. The composition of claim 1 , wherein the cell is a mammalian cell.

18. The composition of claim 1 , wherein the cell is a human cell.

19. The composition of claim 4 , wherein the cell is contained in a syringe or in a biocompatible container.

20. The composition of claim 1 , wherein the network of multi arm polymers comprises methacryloyloxyethyl phosphoscholine co-polymer.

21. The composition of claim 1 , wherein the network of multi arm polymers comprises a combination of PEG and methacryloyloxyethyl phosphoscholine co-polymer.

22. The composition of claim 1 , wherein the network of multi arm polymers consists of polyethylene glycol (PEG), a methacryloyloxyethyl phosphoscholine co-polymer, or a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2021
From: MILLENNIUM PHARMACEUTICALS, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056729/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2019
From: GARIGAPATI, VENKAT R.; MATSUURA, TETSUYA
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 049546/0063 →
Continuity (2)
Provisional Application 62433449 · Dec 13, 2016
Related Publication 20190365955A1 · Dec 5, 2019
Cited By (2)
US 12,338,330 US 12,364,791